Munich - Delayed Quote EUR

Marinomed Biotech AG (93Z.MU)

18.90 0.00 (0.00%)
As of 8:12 AM GMT+2. Market Open.
Currency in EUR All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
9,183.50
9,183.50
11,275.90
11,627.90
8,124.40
Cost of Revenue
8,040.50
8,040.50
9,135.20
10,203.50
8,766.10
Gross Profit
1,143.00
1,143.00
2,140.70
1,424.40
-641.70
Operating Expense
6,254.10
6,254.10
7,012.80
5,549.90
5,174.20
Operating Income
-5,111.10
-5,111.10
-4,872.10
-4,125.50
-5,815.90
Net Non Operating Interest Income Expense
-1,679.70
-1,679.70
-1,518.80
-1,568.50
-190.60
Pretax Income
-6,790.80
-6,790.80
-6,390.90
-5,694.20
-6,006.70
Tax Provision
4.00
4.00
6.80
197.10
3.50
Net Income Common Stockholders
-6,794.80
-6,794.80
-6,397.70
-5,891.30
-6,010.20
Diluted NI Available to Com Stockholders
-6,794.80
-6,794.80
-6,397.70
-5,891.30
-6,010.20
Basic EPS
-4.50
-4.50
-4.30
-4.00
-4.10
Diluted EPS
-4.50
-4.50
-4.30
-4.00
-4.10
Basic Average Shares
1,518.19
1,518.19
1,498.91
1,475.85
1,471.26
Diluted Average Shares
1,518.19
1,518.19
1,498.91
1,475.85
1,471.26
Total Operating Income as Reported
-5,129.20
-5,129.20
-4,913.60
-4,144.70
-5,816.00
Total Expenses
14,294.60
14,294.60
16,148.00
15,753.40
13,940.30
Net Income from Continuing & Discontinued Operation
-6,794.80
-6,794.80
-6,397.70
-5,891.30
-6,010.20
Normalized Income
-6,794.80
-6,794.80
-6,397.70
-5,891.30
-6,010.20
Interest Income
16.90
16.90
0.20
--
0.10
Interest Expense
2,489.90
2,489.90
2,508.20
1,509.00
713.60
Net Interest Income
-1,679.70
-1,679.70
-1,518.80
-1,568.50
-190.60
EBIT
-4,300.90
-4,300.90
-3,882.70
-4,185.20
-5,293.10
EBITDA
-3,622.70
-3,622.70
-3,213.00
-3,576.30
-4,864.70
Reconciled Cost of Revenue
8,040.50
8,040.50
9,135.20
10,203.50
8,766.10
Reconciled Depreciation
678.20
678.20
669.70
608.90
428.40
Net Income from Continuing Operation Net Minority Interest
-6,794.80
-6,794.80
-6,397.70
-5,891.30
-6,010.20
Total Unusual Items Excluding Goodwill
--
--
--
--
-1.00
Total Unusual Items
--
--
--
--
-1.00
Normalized EBITDA
-3,622.70
-3,622.70
-3,213.00
-3,576.30
-4,864.70
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
12/31/2020 - 2/1/2019

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ZLDPF Zealand Pharma A/S
86.08
+6.46%
 
VALN Valneva SE
7.74
-4.06%
 
XENE Xenon Pharmaceuticals Inc.
41.09
+2.70%
 
ABCL AbCellera Biologics Inc.
3.9700
-1.00%
 
ALT Altimmune, Inc.
7.57
+1.34%
 
NVO Novo Nordisk A/S
128.64
+2.70%